EBR Systems (EBR) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
18 Aug, 2026Opening remarks and agenda
The meeting was called to order by the Executive Chair, confirming a quorum and introducing directors and executives present.
The meeting followed the agenda outlined in the notice of meeting dated July 9, 2026.
Specific resolutions to be voted on
Proposal 1: Ratification of the issuance of 77,352,890 CDIs (7,735,289 shares) at AUD 0.38 per CDI under ASX Listing Rule 7.4.
Proposal 2: Approval of the issuance of 92,105,270 CDIs (9,210,527 shares) at AUD 0.38 per CDI to clients of BCP III Property Limited, an associate of a non-executive director, under ASX Listing Rule 10.11.
Corporate governance
Voting was conducted by poll, with eligible common stockholders and proxy holders able to vote online.
All open and available proxies were voted in favor of all items.
An independent returning officer from Computershare Investor Services was appointed.
Latest events from EBR Systems
- Q2 2026 saw FDA approval, 46 WISE implants, and strong commercial and financial progress.EBR
Q2 2026 - FDA review progresses for WiSE CRT System; strong liquidity and capital raise support commercialization.EBR
Q3 2024 TU - Raising A$150m to accelerate leadless CRT device growth in a $5.8bn US market.EBR
Investor presentation - Q1 revenue neared $2.4M as case volumes doubled and WISE System adoption accelerated.EBR
Q1 2026 TU - FDA approval, reimbursement, and commercial milestones set the stage for expansion by 2026.EBR
AGM 2026 - FDA approval and U.S. launch drove $1.6M revenue but net loss reached $48.8M in 2025.EBR
Q4 2025 TU - Shareholders voted on a reverse stock split and ratification of a prior securities issuance.EBR
EGM 2026 - Only FDA-approved, fully leadless CRT device, targeting a $5.8bn US market with rapid growth.EBR
Investor presentation - Shareholders to vote on consolidating common shares for future flexibility; ASX CDIs unaffected.EBR
EGM 2026